Oramed Pharmaceuticals (NASDAQ:ORMP) is a biotech firm focused on the development of oral drug delivery systems, including an innovative oral insulin capsule designed to improve the treatment and management of diabetes. The company's groundbreaking approach aims to replace injectable treatments with oral alternatives, fundamentally changing the way chronic diseases are managed. Their portfolio also explores similar technologies for other medications requiring injections, with the ultimate goal of enhancing patient convenience, compliance, and overall health outcomes. Oramed Pharmaceuticals is committed to advancing these projects through clinical trials and partnerships, with the objective of making oral medication options available to a broader patient population worldwide.